메뉴 건너뛰기




Volumn 1, Issue 7, 2012, Pages 1181-1182

Interleukin-2 treatment of tumor patients can expand regulatory T cells

Author keywords

Immunotherapy; Interleukin 2; Treg cells; Tumor

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOKINE; INTERLEUKIN 2; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR FOXP3;

EID: 84883553471     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.20639     Document Type: Article
Times cited : (12)

References (10)
  • 1
    • 41949097030 scopus 로고    scopus 로고
    • The biology of interleukin-2
    • Malek TR. The biology of interleukin-2. Annu Rev Immunol 2008; 26:453-79; PMID:18062768; http://dx.doi.org/10.1146/annurev.immu-nol.26.021607.090357.
    • (2008) Annu Rev Immunol , vol.26 , pp. 453-479
    • Malek, T.R.1
  • 2
    • 84859416933 scopus 로고    scopus 로고
    • Regulatory T cells: mechanisms of differentiation and function
    • Josefowicz SZ, Lu L F, Rudensky AY. Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol 2012; 30:531-64; PMID:22224781; http://dx.doi.org/10.1146/annurev.immu-nol.25.022106.141623.
    • (2012) Annu Rev Immunol , vol.30 , pp. 531-564
    • Josefowicz, S.Z.1    Lu, L.F.2    Rudensky, A.Y.3
  • 3
    • 68449099413 scopus 로고    scopus 로고
    • Regulatory T cells: major players in the tumor microenvironment
    • Beyer M, Schultze JL. Regulatory T cells: major players in the tumor microenvironment. Curr Pharm Des 2009; 15:1879-92; PMID:19519430; http://dx.doi.org/10.2174/138161209788453211.
    • (2009) Curr Pharm Des , vol.15 , pp. 1879-1892
    • Beyer, M.1    Schultze, J.L.2
  • 4
    • 33644784733 scopus 로고    scopus 로고
    • + regulatory T cells in cancer patients
    • + regulatory T cells in cancer patients. Blood 2006; 107:2409-14; PMID:16304057; http://dx.doi.org/10.1182/blood-2005-06-2399.
    • (2006) Blood , vol.107 , pp. 2409-2414
    • Ahmadzadeh, M.1    Rosenberg, S.A.2
  • 6
    • 44249085912 scopus 로고    scopus 로고
    • Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma
    • Sosman JA, Carrillo C, Urba WJ, Flaherty L, Atkins MB, Clark JI, et al. Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma. J Clin Oncol 2008; 26:2292-8; PMID:18467720; http://dx.doi.org/10.1200/JCO.2007.13.3165.
    • (2008) J Clin Oncol , vol.26 , pp. 2292-2298
    • Sosman, J.A.1    Carrillo, C.2    Urba, W.J.3    Flaherty, L.4    Atkins, M.B.5    Clark, J.I.6
  • 7
    • 34547629044 scopus 로고    scopus 로고
    • + T-cell pool and tumor trafficking in patients with ovarian carcinoma
    • + T-cell pool and tumor trafficking in patients with ovarian carcinoma. Cancer Res 2007; 67:7487-94; PMID:17671219; http://dx.doi.org/10.1158/0008-5472.CAN-07-0565.
    • (2007) Cancer Res , vol.67 , pp. 7487-7494
    • Wei, S.1    Kryczek, I.2    Edwards, R.P.3    Zou, L.4    Szeliga, W.5    Banerjee, M.6
  • 8
    • 84856039913 scopus 로고    scopus 로고
    • + regulatory T cells in patients with colorectal carcinoma after IL-2 administration
    • + regulatory T cells in patients with colorectal carcinoma after IL-2 administration. PLoS One 2012; 7:30422; PMID:22276195; http://dx.doi.org/10.1371/journal.pone.0030422.
    • (2012) PLoS One , vol.7 , pp. 30422
    • Beyer, M.1    Schumak, B.2    Weihrauch, M.R.3    Andres, B.4    Giese, T.5    Endl, E.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.